The FDA approved FoundationOne CDx as a companion diagnostic to guide treatment selection for certain patients with non-small cell lung cancer.The approval applies to use of FoundationOne CDx (Foundation Medicine) to identify patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R alterations and are appropriate for treatment with FDA-approved EGFR tyrosine kinase inhibitors
Few areas in cardiology are as active as development and implementation of medical therapies for heart failure, and few people are as familiar with that…
Patient care technician staffing at U.S. dialysis facilities varies by geography, time and other attributes, data show. Further investigation could lead to better quality of…
The Mine Safety and Health Administration within the U.S. Department of Labor has finalized stricter limits on silica dust exposure for miners, according to a…
Compared with healthy individuals, having undiagnosed COPD or asthma negatively impacted quality of life and led to higher health care usage, according to results published…
More than 1,600 health care professionals celebrated the approval of Rezdiffra, the first treatment for adults with metabolic dysfunction-associated steatohepatitis, according to a global online…
BOSTON — Most people in the United States do not get enough vitamin D, but supplementation helps patients reach the daily recommended dietary allowance, according…
In this Healio Video Perspective from the ASCRS meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis of two clinical trials investigating…
Among patients with chronic coronary syndrome, women were less likely than men to be treated with lipid-lowering therapy, researchers reported at ESC Preventive Cardiology 2024.Women…
Decades of declining heart failure mortality in the U.S. has reversed, and exceeded rates recorded more than 20 years ago, according to overall population-level data…
Few areas in cardiology are as active as development and implementation of medical therapies for heart failure, and few people are as familiar with that…
